key: cord-0969177-0qdudcuk
authors: Vicenti, Ilaria; Martina, Maria Grazia; Boccuto, Adele; De Angelis, Marta; Giavarini, Giorgia; Dragoni, Filippo; Marchi, Serena; Trombetta, Claudia Maria; Crespan, Emmanuele; Maga, Giovanni; Eydoux, Cecilia; Decroly, Etienne; Montomoli, Emanuele; Nencioni, Lucia; Zazzi, Maurizio; Radi, Marco
title: System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2
date: 2021-07-05
journal: Eur J Med Chem
DOI: 10.1016/j.ejmech.2021.113683
sha: 0da3c294419e5e525b1e99adc7a945d0ef927da0
doc_id: 969177
cord_uid: 0qdudcuk

The worldwide circulation of different viruses coupled with the increased frequency and diversity of new outbreaks, strongly highlight the need for new antiviral drugs to quickly react against potential pandemic pathogens. Broad-spectrum antiviral agents (BSAAs) represent the ideal option for a prompt response against multiple viruses, new and re-emerging. Starting from previously identified anti-flavivirus hits, we report herein the identification of promising BSAAs by submitting the multi-target 2,6-diaminopurine chemotype to a system-oriented optimization based on phenotypic screening on cell cultures infected with different viruses. Among the synthesized compounds, 6i showed low micromolar potency against Dengue, Zika, West Nile and Influenza A viruses (IC(50) = 0.5–5.3 μM) with high selectivity index. Interestingly, 6i also inhibited SARS-CoV-2 replication in different cell lines, with higher potency on Calu-3 cells that better mimic the SARS-COV-2 infection in vivo (IC(50) = 0.5 μM, SI = 240). The multi-target effect of 6i on flavivirus replication was also analyzed in whole cell studies (in vitro selection and immunofluorescence) and against isolated host/viral targets.

J o u r n a l P r e -p r o o f categories A and B emerging infectious pathogens, accounting for 17% of infections worldwide and for which no drugs or universally protective vaccines are currently available. The epidemic potential of these flaviviruses is well represented by the increasing number of autochthonous vector-borne flavivirus infections in the last decade. 6, 7 An additional problem with flavivirus infections is represented by coinfections, not only by different viruses in the same family (e.g. DENV/ZIKV 8, 9 ) , but also by different virus families (e.g. DENV/SARS-CoV-2 10, 11 or DENV/influenza 12 ), which creates immune response disorders, confusion in diagnosis and delays in treatment, leading to additive or synergistic morbidities. 13, 14 These diagnostic and therapeutic issues are even more serious in the case of newly emerging potentially pandemic viruses or in case of emerging variants with higher mortality rate since the time needed to develop a specific vaccine or drug is not compatible with a prompt response. Therefore, development of pan-viral drugs (broad-spectrum antiviral agents; BSAAs) capable of inhibiting the replication of multiple viruses belonging to different families, is an ambitious but attractive option in preparedness for outbreaks of previously unknown viral diseases and also for the treatment of widespread viral infections where an effective drug is not available yet. However, to date, the rarely used and mildly effective Ribavirin (RBV) is the only BSAA approved for the treatment of infections caused by different virus families. Other nucleoside antivirals, despite acting on the highly conserved viral transcription process, are approved for the treatment of infections caused by a single virus family.

On the other hand, a number of experimental non-nucleoside BSAAs with mechanism of action (MOA) that is often complementary to that of nucleoside inhibitors are also under clinical development for the treatment of multiple virus families, even if sometime their MOA is not fully understood due to their effect on multiple targets (e.g. Nitazoxanide, 71 To come up with new antivirals needed to fight the growing circulation of different viruses, the antiviral drug discovery community has been gradually revising its original "one-drug, one virus" dogma, based on targeting specific viral proteins with a single drug, passing through different paradigm shifts: i) the "one-drug, multiple viruses" paradigm, based on the design of molecules targeting viral proteins highly conserved among different viruses (e.g. RNA/DNA polymerases);

ii) the "host-targeting antivirals" paradigm, based on targeting host-proteins (e.g. CCR5 with Maraviroc) used by many viruses for their replication; 15 iii) the "hypothesis-free drug repositioning" approach, based on testing safe in man compounds as antiviral candidates, independently from their original indication, for an accelerated approval. The latter approach is being strongly pursued to quickly discover new antivirals for emerging diseases, despite no clinical success has been reported in the last two decades. 16 A recent addition to the field is the "one-drug, multiple-targets" paradigm (polypharmacology), which represents a more realistic approach that takes into account the high number of on-and off-targets interacting with a drug candidate and the presence of compensatory pathways that may limit the effectiveness of highly specific drugs. 17, 18 In fact, it is not uncommon that looking back at old antivirals (e.g. Ribavirin; Figure 1 ) with this new awareness, new pharmacological targets or mechanisms are found involved in determining the observed therapeutic effect and, possibly, the pan-antiviral activity. 19 Partial inhibition of multiple targets with a single multi-target drug seems more effective than full inhibition of a single target, reducing on-and off-target-related toxicity and attrition rate in clinical development. 17 In line with this paradigm shift in antiviral drug discovery, our research group has successfully reported the development of multi-target antivirals active on multiple viruses and related diseases in vitro. 20, 21, 22, 23 As a continuation of our previous work in this field, we describe herein a phenotypic-based study focused at the optimization of 2,6-diaminopurine multi-target anti-flavivirus agents (e.g. 1-3, phenotypic drug discovery (PDD), a first generation of purine-based multi-target antivirals (e.g. compounds 1-2, Figure 1 ) was previously reported by us. 20 These compounds proved to inhibit DENV replication (the only affected virus), blocking the interaction between the recombinant viral proteins NS5/NS3 and inhibiting, at the same time, the activity of host c-Src/Fyn kinases. The following target-based optimization based on the allosteric cavity B of NS5 led to a second generation of derivatives (e.g. compound 3, Figure 1 ) with a wider spectrum of activity, blocking the replication of all four DENV serotypes and ZIKV. 22 Unfortunately, this targeted optimization did not allow to improve the antiviral potency of the second generation derivatives as we expected from the modeling predictions. A summary of antiviral potency for compounds 1-3 is reported in Figure 1 . Here we reasoned that a more efficient approach to optimize multi-target antivirals could be based on phenotypic considerations resulting from functional screening of focused derivatives since: i) the antiviral effect in a cellular context may be the result of a synergic activity on multiple targets; ii) unexpected targets or novel modes of action can be responsible for the antiviral effect.

To further explore the antiviral potential of the 2,6-diaminopurine chemotype we planned to build a new series of derivatives by combining the C2 substituents of the hit compounds 1-3 with different substituted anilines in C6 (Scheme 1). Compounds 6a-k were thus obtained by applying the fast and efficient two-step microwave-assisted protocol previously developed, starting from commercially available 2,6-dichloropurine (4). 20 Compounds 6l,m were then obtained by hydrolysis of the corresponding methyl esters 6d,f. In addition, we also prepared the two "inverted" derivatives of compounds 6c and 6i where C2 and C6 substituents were exchanged: J o u r n a l P r e -p r o o f starting from 4, the phenoxyethylamino chain was initially introduced in C6 (compound 7)

followed by C2 nucleophilic substitution with the opportune substituted aniline to give the desired "inverted" compounds 8a,b (Scheme 1). Scheme 1. a Reagents and conditions: i.) amines, n-BuOH, Et3N, 70-100 °C, 10-50 min, μW; ii.) amines, n-BuOH, TFA, 150-170°C, 40-70 min, μW; iii.) 6d or 6f, LiOH, THF/MeOH, r.t., 24h (for 6l,m)

Compounds 6a-m and 8a,b where then analyzed for their anti-DENV and anti-ZIKV activity in a Huh7 hepatoma cell-based secondary yield reduction assay (SYRA) 24 which quantifies infectious culture supernatants by immunodetection (Table 1 ). All non-toxic compounds tested showed promising antiviral activity against both DENV and ZIKV. Within the 3'-F and 3'-CF3 series (compounds 6a-c and 6g-i, respectively) the selectivity index (SI) with both viruses increased with the length of the C2 side chain. The 3'-CO2Me series (compounds 6d-f) was characterized by a J o u r n a l P r e -p r o o f similar potency on ZIKV and, surprisingly, the 2-phenoxyethylamino derivative 6f did not show any activity on DENV. Compared to the 3'-CO2Me series, the 3'-CO2H series (compounds 6l-m) showed a reduced potency and opposite specificity since the 2-phenoxyethylamino derivative 6m was active against both DENV and ZIKV (compared to 6f) while the 2-methylamino derivative 6l was active only against ZIKV (compared to 6d). Also the 3',4'-OH derivative 6j was active only against ZIKV while the trimethoxy derivative 6k was quite cytotoxic. It was also interesting to note that the two "inverted" compounds 8a,b, analogues of the active compounds 6c and 6i, showed high cytotoxicity and were not evaluated for antiviral potency. Out of these 15 tested compounds, 6i showed the most potent antiviral activity against both ZIKV (SI 182) and DENV (SI 77) with IC50 values in the low micromolar range, comparable to or slightly better than those of the reference drugs Sofosbuvir and Ribavirin. Based on these results and on those reported by us for the previous generations of 2,6-diaminopurine antivirals, a few rough SAR considerations can be drawn: i) substituted anilines in C2 lead to cytotoxic compounds (e.g. 8a,b and 12c-e ref.

; ii) cyclic secondary amines in C2 lead to inactive or poorly active antivirals (e.g. 12f ref. 22, 16a-c ref. 20); iii) increasing the length of the C2 substituent (primary amines) increase the selectivity index and the antiviral spectrum; iv) different functional groups on the C6 aniline moiety are well tolerated for the antiviral activity (see Table 1 ), with a few exceptions (e.g. 6k).

As previously reported, comparison between SYRA and direct yield reduction assay (DYRA) data can be used to obtain preliminary information about early versus late antiviral activity of drug candidates. 24, 25, 26 Compound 6i was thus analyzed through DYRA against ZIKV and DENV replication. As shown in Table 1 , 6i confirmed the antiviral potency seen in SYRA against ZIKV but it did not show any antiviral activity against DENV in DYRA. These results suggest that 6i J o u r n a l P r e -p r o o f exerts the antiviral activity against DENV not at early stages of viral replication and probably at a later stage than Sofosbuvir, which showed the same potency in SYRA and DYRA, as expected. 21 30 a CC50: half-maximal cytotoxic concentration (μM); b IC50: half-maximal inhibitory concentration calculated through SYRA; each value is the mean of three experiments ± standard deviation (SD); c SI: selectivity index (SI = CC50/IC50). d NA: not active; e ND: not determined; f IC50: half-maximal inhibitory concentration calculated through DYRA; g IC50: half-maximal inhibitory concentration calculated through PRA. DMSO was used as control in all cytotoxicity and antiviral assays.

The anti-DENV efficacy of 6i was finally confirmed by plaque reduction assay (PRA), giving an IC50 of 0.90 ± 0.04 μM (in agreement with SYRA) that is four-fold the IC50 and SI of both Sofosbuvir and Ribavirin. Curiously, 6i showed low micromolar potency in SYRA/PRA but also in DYRA against ZIKV, suggesting an effect on replication of this virus at an earlier stage compared to DENV. The antiviral activity of the most potent DENV inhibitors 6h and 6i was also assessed against WNV through DYRA and PRA in comparison with Sofosbuvir/Ribavirin. All compounds were active in the low micromolar range but, again, 6i proved to inhibit WNV replication in PRA and not in DYRA, matching the result obtained with DENV. Overall, this phenotypic optimization led to the identification of 6i as the most interesting broad-spectrum antiflavivirus candidate, whose potency and SI was generally superior to that of Sofosbuvir and Ribavirin.

In the attempt to further investigate and expand the multi-target propensity of the 2,6diaminopurine class of molecules (generally referred to as privileged structure), we aimed at introducing small structural modifications that may confer additional antioxidant properties to 6i and closely related analogues. The induction of oxidative stress is in fact recognized as a common trigger of exacerbation in diseases caused by different viruses, including flavivirus, coronavirus and, particularly, Influenza virus. 27 A few literature reports show that opportune functionalization of the purine scaffold can lead to derivatives also endowed with antioxidant properties by scavenging reactive oxygen species (ROS). 28, 29, 30 Among the many possible functionalization options, we were intrigued by a recent work from the Feringa group, describing the development of photoswitchable purine derivatives bearing an azobenzene moiety in C6. 31 The synthesis of these compounds pass through a 6-phenylhydrazino intermediate that is easily converted into the desired azobenzene derivative by O2-mediated oxidation: although the hydrazine motif is generally J o u r n a l P r e -p r o o f considered a toxicophore moiety, we thought that opportunely substituted C6-phenylhydrazino derivatives may counteract the virus-induced oxidative stress converting themselves into stable azo-derivatives. This choice was also supported by the low cytotoxicity of 6-phenylhydrazino purines previously reported as anti-malaria agents. 32 The synthesis of our target compounds 10ae followed the same synthetic sequence used for the synthesis of 6a-m: microwave-assisted C6 nucleophilic substitution on 4 with substituted phenylhydrazines afforded intermediates 9a-e that were finally converted into 10a-e by reaction with phenoxyethylamine at high temperature for 90 minutes (Scheme 2). The latter compounds were slowly converted into stable aza-derivatives 11ad by simply stirring their methanolic solution at room temperature under air for 96 hours. It was interesting to note that, under the same oxidative conditions, the 3-CF3 derivative 11e tend to decompose and the corresponding azo-derivative 11e was not isolated. Compounds 10a-e and 11a-d were then submitted for biological evaluation against flaviviruses.

Unfortunately, most of the compounds displayed high cytotoxicity in Huh7 cells and were not tested for inhibition of virus replication. Only 3'-F derivatives 10a and 11a, which showed J o u r n a l P r e -p r o o f acceptable cytotoxic effect, were analyzed for their anti-flavivirus potency ( Table 2) : both compounds displayed low micromolar activity against DENV, ZIKV and WNV with the highest SI against the latter virus. Interestingly, the target compound 10a and the corresponding oxidized derivative 11a showed the same antiviral activity, supporting the idea that 10a may exert a synergic antiviral/antioxidant activity in infected cells and then being converted into a stable metabolite (11a) that still displays antiviral activity (dual action). The potential antioxidant effect of compound 10a was then experimentally evaluated in terms of 'radical scavenging activity' (RSA) using a ABTS radical decolorization method in comparison with 11a, 6i and with a potent antioxidant molecule (ascorbic acid) used as reference. 33 Table 2 . DENV-2/ZIKV/WNV replication inhibitory effect. 8

18. As reported in Figure 2 , compound 10a showed a clear concentration-dependent radical scavenging activity that was not observed for 11a and 6i. In addition, the stability of 11a towards oxidative stress was further assessed by reaction with H2O2 in argon atmosphere: while compound 10a was quickly converted into 11a, the latter compound and 6i were stable for days in the presence of 40 mM H2O2 in ethanol (data not shown). To further explore the spectrum of antiviral activity of the most promising inhibitors herein reported, compounds 6c, 6i, 10a were also evaluated against a segmented negative RNA virus (Influenza A Puerto Rico/8/34 H1N1, PR8). MDCK and A549 cell lines were used to evaluate compounds' cytotoxicity and antiviral potency. The BSAA Ribavirin (RBV) is reported in Table  concentration . In particular, 6i and 10a showed higher SI and IC50 with respect to 6c, and a stronger anti-influenza activity in comparison with RBV. Since compound 10a inhibited replication when added after the infection and due to its antioxidants activity, we hypothesize its role in maintaining reducing conditions into the cells. In fact it has been demonstrated that influenza virus induces redox changes in terms of ROS production and glutathione depletion, to activate redox-sensitive pathways useful for viral replication. 35 Further studies are in progress to evaluate this hypothesis.

To get further insights on the effect of compound 6i on Influenza virus replication, it was added at different times: i) 2 hours before infection (PRE); ii) for 1 hour during viral adsorption (DUR); iii) after viral infection for 24 hours (POST) or iv) before, during and after infection for the following 24 hours (PDP). Supernatants from infected cells were recovered at 24 hour from infection and used to infect a fresh cell monolayer. The expression of viral protein (hemagglutinin; HA) was quantified as percentage of relative fluorescence units (RFU) analyzed by ICW, as described in Methods Section. As shown in Figure 3A , the percentage of HA was similarly reduced (50% inhibition) when 6i was added during (DUR) or post infection (POST). On the contrary, pretreatment alone (PRE) was not quite effective. Next, specific steps of infection were evaluated by using a time-of-addition assay. In particular, compound 6i was added: i) immediately after infection for 2, 4 and 6 hours on A549 cell monolayers and then maintaining cells in fresh medium without the compound until 24 hours from infection; ii) after 2, 4 and 6 hours from infection and maintaining the compound until 24 hours from infection. Supernatants were recovered and used to infect fresh monolayers of MDCK cells. As shown in Figure 3B , the percentage of HA expression was mostly reduced when 6i was added within the first 6 hours from infection. Indeed, if the compound was added after 6 hours, we did not find a significant inhibition, suggesting that the early phases of infection were impaired by 6i addition. Table 3 . Influenza A virus and SARS-CoV-2 replication inhibitory effect. a CC50: half-maximal cytotoxic concentration (μM); b IC50: half-maximal inhibitory concentration, each value is the mean of three experiments ± standard deviation (SD) at 0.01 MOI; c SI: selectivity index (SI = CC50/IC50); d IC50: half-maximal inhibitory concentration calculated through DYRA; e ND: Not determined; f IC50 calculated incubating with the ENTRY-DYRA protocol. Literature antiviral data for Remdesivir (RMD) and Ribavirin (RBV) are reported in parenthesis. CMT: Camostat. DMSO was used as control in all cytotoxicity and antiviral assays. . Compound 6i interferes with early steps of influenza virus replication. A549 cells were infected with PR8 and treated or not with 6i (20 μM) at different phases of the virus lifecycle: the compound was added for 2 hours before (PRE); during viral adsorption for 1 hour (DUR); immediately after viral adsorption for 24 hours (POST); before, during and for the following 24 hours (PDP). The supernatants were recovered and used to infect fresh A549 monolayers for the following 24 hours (A); compound 6i was immediately added after viral adsorption for 2 (0-2h), 4 (0-4h) or 6 (0-6h) hours. Then cells were maintained up to 24 hours without 6i in fresh medium plus 2% FBS; compound 6i was added after 2 (2-24h), 4 (4-24h) or 6 (6-24h) hours infection and maintained until 24 hours from infection. The supernatants were recovered and used to infect fresh MDCK monolayers for 24 hours (B). The expression of hemagglutinin (HA) was analyzed by ICW, using LI-COR Image Studio Software, as described in Methods. The percentage of relative fluorescence units (RFU) was calculated in comparison to untreated-infected cells (PR8 H1N1) (considered 100%). Data represent the mean ± S.D. of 3 replicates (A) or 4 replicates (B) obtained from two experiments performed. Statistical significance of the data vs PR8 H1N1 was defined as *P < 0.05 and **P < 0.01. . Compound 6i is effective against different influenza A virus strains. A549 cells were infected with influenza A virus strains as described in Methods and treated or not with 6i (20 μM) at different phases of the virus life-cycle: A) compound 6i was added for 2 hours before (PRE); during viral adsorption for 1 hour (DUR); immediately after viral adsorption for 24 hours (POST); before, during and for the following 24 hours (PDP). Infected treated cells were fixed and stained with anti-FLU antibodies as already described; B) compound 6i was immediately added after viral adsorption for 2 (0-2h), 4 (0-4h) or 6 (0-6h) hours. Then cells were maintained without the compound up to 24 hours in fresh medium plus 2% FBS; the compound was added after 2 (2-24h), 4 (4-24h) or 6 (6-24h) hours infection and maintained until 24 hours from infection. The supernatants were recovered and used to infect fresh MDCK monolayers for 24 hours. The expression of FLU proteins was analyzed by ICW, using LI-COR Image Studio Software. The percentage of relative fluorescence units (RFU) was calculated in comparison to untreated-infected cells (considered 100%). Values are the mean ± S.D. of 2 replicates (A) or 3 replicates (B) obtained from one of the two experiments performed. Statistical significance of the data vs untreatedinfected cells was defined as *P < 0.05, ** P < 0.01 and ***P < 0.001.

Finally, the BSAA 6i was selected as the most interesting candidate to be evaluated against SARS-CoV-2: it was noteworthy to find that 6i inhibited the replication of this new coronavirus in the low micromolar range in all human cell lines evaluated (Table 3) Overall, phenotypic screening of the synthesized purine derivatives against different RNA viruses and different cell lines, clearly identified compound 6i as the most promising BSAA that can be quickly produced by two simple synthetic steps in only 60 minutes. Although 6i is just a promising lead compound, its cheap and easy synthetic accessibility is particularly relevant in comparison with the many synthetic steps that are needed to synthesize the reference nucleoside antivirals Sofosbuvir 40 and Remdesivir. 41 Considering the high anti-DENV and anti-ZIKV activity of 6i in Huh7 (SI 222 and 400 respectively in PRA), in vitro selection experiments were performed to investigate the 6i genetic barrier. ZIKV and DENV inputs (0.05 MOI), each in duplicate, were used to infect Huh-7 cells in the presence of increasing concentration of 6i, starting from 15 μM of 6i up to 120 μM. Uninfected cells treated with 6i were used as negative control to discriminate between cytopathic effect (CPE) derived from 6i cytotoxicity and physiological cell mortality. 6i pressure delayed viral growth with respect to the no-drug virus control (VC). Indeed, around 80% CPE was reached at 5-9 days post infection (dpi) with 15-120 μM 6i while the VC was consistently collected at 2-4 dpi ( Table 5 ). In vitro selection experiments were stopped after a mean of 23.8±1.5 dpi when the drug pressure was J o u r n a l P r e -p r o o f 133-fold and 240-fold higher than 6i IC50 against DENV and ZIKV wild type, respectively.

Aminoacidic (aa) variations in NS5 and NS3 regions selected under 6i pressure are indicated in Table 5 . It must be noted that some mutations were transiently or permanently observed in the absence of drug pressure, suggesting that changes in the viral genome driven by virus adaptation to the cell line used or stochastically also occur.

Even if at different timing, both ZIKV and DENV escaped from 6i drug pressure, selecting mutation mixtures which were then lost at subsequent drug increment steps. When considering mutation profiles including pure mutations, the 2 viral strains emerging at 120 µM (I600V in DENV NS3) and at 15 µM (T860P in ZIKV NS5) were not quantifiable by IA. The same occurred with the virus carrying the mixed aa profile selected in ZIKV NS5 at 60 µM 6i (D245D/A combined with D788D/E). On the basis of these observations, we can hypothesize that these profiles selected by 6i impair the viral fitness resulting in lack of CPE at subsequent infection rounds. In this context, CPE is probably caused not only by replicating virus but also by the accumulation of viral transcripts and non-replication competent viruses. The mixed and pure mutations selected under 6i drug pressure were distributed in different NS5 domains for ZIKV and DENV.

With the exception of DENV E427E/K and ZIKV D788D/G/E, all mutations selected in NS5 occurred at conserved sites among different flaviviruses. 42 The majority of NS5 aa variations selected (D788D/G, D788D/E, T792T/P, M806M/I, T860P for ZIKV and E427E/K for DENV) were located in the polymerase region (RdRp); none of them were located in the catalytic site. 43 The E427 is located between the G and F motifs of DENV RdRp: these two motifs interact with the nascent RNA template. D788, T792, M806 and T860 are located in the ZIKV priming loop which is involved in the correct positioning of nucleotides during polymerization. Interestingly, J o u r n a l P r e -p r o o f the T860P mutation emerged in ZIKV is located in the allosteric RdRp cavity B: it has been observed that mutated residues located in this cavity near T860 (W859A, I863A in DENV) significantly reduced viral replication and this could explain the fitness impairment of strains carrying this mutational profile. 44 45 Under 6i drug pressure, no pure or mixed mutations were selected in ZIKV NS3. The mixed R54R/P substitution selected in DENV NS3 is located in the N terminal domain near the catalytic site (His53, Asp77 and Ser138) of the trypsin-like serine protease. 43 The mixed substitution M267M/I is located in the C terminal subdomain I of NS3; the conserved motifs in subdomains I and II are key regions for binding to RNA to generate the ATP binding cleft. 46 It's important to underline that, the only pure aa variation I600V acquired in the presence of 120 µM 6i by DENV is located in the subdomain 3 of the helicase region of the NS3 protein and between two α-helices (559 to 607 residues) α9 and α10. 47 Interestingly, the subdomain III (NS3 483-618 aa) contains the interaction site with NS5 (320-368 aa) of the RdRP domain. 48, 49 In comparison to our previously published work 24 investigating the genetic barrier of sofosbuvir against WNV with the same methodology, 6i seems not to have a high genetic barrier. Indeed the selected mutations were lost in the subsequent culture passages with increasing drug concentration.

In addition, the time of viral breakthrough in the presence of 6i was not significantly increased with respect to VC. However, the I600V substitution for DENV NS3 and the D788D/G/E alone or coupled with the T860P substitution for ZIKV NS5 reduced dramatically the viral fitness. Indeed, mutated profiles were not able to replicate in subsequent cultures in the presence of 6i and reverted J o u r n a l P r e -p r o o f 

to wild type when grown in the absence of 6i (data not shown). While the mutations emerging from this study cannot explain the mechanism of action of 6i in detail, their location supports the targeting of the replication machinery and the interaction between NS3 and NS5 as per our original design. 20 To further corroborate the interaction between 6i and DENV/ZIKV NS5, we evaluated the inhibition of both MTase and polymerase enzymatic activity in cell free experiments.

Compounds 6c, 10a and 11a were tested as comparison together with the lead compound 6i (Table   6 ). Increasing concentrations of inhibitor were incubated with the purified MTase or polymerase and the respective enzymatic activity was determined as previously described. 50, 51 The IC50 of compounds, deduced from Hill slope curve-fitting, are presented in Table 6 . The results show that the compounds barely inhibit the MTase activity. Conversely we observed that 6c and 6i inhibit the polymerase of DENV and ZIKV at a micromolar concentrations slightly higher than the corresponding IC50s in cell, further suggesting a multi-target mechanism for the inhibition of DENV/ZIKV replication. . Immunofluorescence analysis. DENV-2 infected cells were treated with 6i (50 µM) and stained at different time points with DENV NS3 antibody (detected using AlexaFluor® 488 labeled secondary antibody) and DENV NS5 antibody (detected using AlexaFluor® 568 labeled secondary antibody), and examined by confocal microscopy. NS3:NS5 stained cells merged images and white dots colocalization (WDC) images in untreated control (above) and treated with 6i compound (below) are shown as indicated. Each experiment was repeated at least two times.

It was interesting to observe that, although 6i and Sofosbuvir showed a similar effect on the reduction of NS5/NS3 expression over time, they induced a completely different effect on the localization of the same proteins, which reflects the different mechanism of action of the two compounds and indirectly support the difference seen in the DYRA/SYRA assays and the mutational profile that is observed under 6i pressure (not compatible with that of a nucleoside inhibitor).

Finally, to verify the multi-target effect of this class of compounds, the most interesting 2,6diaminopurine derivatives synthesized in this work (6c, 6i, 10a and 11a) were also evaluated against selected host kinases that are known from the literature to be involved in the replication of flaviviruses, Influenza viruses and Coronaviruses (Table 7) . 58, 59, 60 The above compounds were tested at fixed concentration corresponding to their median antiviral IC50 (5 M) in comparison with the hit 3. Despite potent nanomolar kinase inhibitors with no antiviral activity have been reported among 2,6-diaminopurine derivatives, 61 our compounds showed a moderate inhibitory effect on the selected kinases at micromolar concentration: in particular, compound 6i reduced the activity of Src, Abl and PI3K by roughly 50% at 5 M. The get a wider picture on the kinase specificity of 6i, it was also tested against an additional panel of 15 host kinases selected among those known from the literature to be involved in the replication of different viruses (Table S3, Supporting Information). 74 However, no significant inhibition of these additional targets was found testing 6i at 5 M concentration, making Src, Abl and PI3K the only kinases (among the few selected) that are mildly inhibited by our lead compound. This moderate host kinases inhibition together with the observed effect on NS5/NS3 may therefore account for the anti-flaviviral effect J o u r n a l P r e -p r o o f of these multi-target inhibitors. As expected from the literature, 58-60 the effect of 6i on the above kinases could also play a partial role in inhibiting the replication of Influenza A and SARS-CoV-2 but the full understanding of its MOA is a complex endeavour and major efforts will be required to solve this challenge in the future. It is also important to remember that the precise knowledge of a drug's target is not an essential requirement in drug discovery and around 10-20% of approved drugs have unknown target or MOA. 62, 63 Especially in the discovery of new BSAAs for emerging diseases, the right compromise between target identification and efficacy in multiple functional assays should probably drive the rapid development of new and efficient candidates for preclinical studies. proteins in an AlphaScreen assay at high micromolar concentration. 20 The following target-based optimization study led to the identification of compound 3 as a promising derivative active against all four DENV serotypes and ZIKV but possessing a potency (IC50 DENV-2 = 10 M; IC50 ZIKV = 16.7 M) comparable to that of compounds 1 and 2. 22 Considering the sub-optimal results of this target-based optimization and the advantages of a system-oriented investigation in deciphering the functional efficacy of multi-target antivirals, we have reported here a phenotypic hit-to-lead optimization that has allowed us to identify compound 6i as a promising BSAA active against all tested viruses in the submicromolar to low micromolar range (IC50 = 0.5-5.3 M).

Starting from preliminary SAR consideration on previously published 2,6-diaminopurine antivirals , we developed a first set of molecules (6a-m; 8a,b) that showed improved antiviral potency against selected flaviviruses (DENV-2, ZIKV and WNV). We then explored the possibility to functionalize the 2,6-diaminopurine scaffold with a ROS scavenging moiety to relieve the cellular oxidative stress generated by viral infections. Within this second set of molecules (10a-e; 11a-d), only two derivatives (10a and 11a) showed interesting antiviral results against selected flaviviruses.

The three most promising compounds identified from the phenotypic screening against flaviviruses (6c, 6i and 10a) were then evaluated against Influenza A (human and avian viruses) thus identifying 6i as the most potent and promising candidate, which retained activity on different Influenza strains (the human PR8 H1N1 and the pandemic 2009 H1N1 or the avian Ulster H7N1).

Compound 6i was also tested against the novel coronavirus SARS-CoV-2 proving to inhibit its replication at low micromolar and submicromolar concentrations in all human cell lines evaluated. (C19H15F2N7O) C, H, N.

MS (ESI) [M+H] 

To determine the antiviral activity of candidate compounds against WNV, DENV and ZIKV, a DYRA based on infection of cells in presence of serial drug dilutions was performed as previously described. 24 

This is an innovative cell-based technique that allows a sensitive quantification of influenza virus proteins expressed on cell monolayers. 69 The expression of viral proteins was analyzed directly on the infected cell monolayers or on other monolayers infected for 24 hours with the recovered supernatants. Statistical significance of the data was analyzed by means of a one-way ANOVA Multiple comparisons test and *P values of < 0.05 were considered significant. Data were expressed as mean ± the standard deviation (SD).

J o u r n a l P r e -p r o o f

The in vitro selection experiments were performed as previously described. 67 Huh7 cells at 70% confluence were infected in duplicate with ZIKV and DENV at 0.005 multiplicity of infection (MOI). After 1 h adsorption at 37°C with 5% CO2, the virus inoculum was removed and cells were treated with an initial concentration of 15 µM 6i, corresponding to 17-fold and 30-fold IC50 (as observed by PRA) against DENV and ZIKV, respectively. Cell cultures were monitored every 24 hours and when 80% viral CPE was observed, cells and supernatant were freeze-thawed, cleared by centrifugation and viral stocks were used to re-infect fresh pre-seeded Huh7 cells with a twofold increased 6i concentration (30, 60 and 120 µM). All viral stocks collected during in vitro selection experiments were analysed by population sequencing to detect emergent mutations in the NS5 and NS3 regions. Wild type and mutant viruses were titrated by IA. values. Costes P values ≥95% were considered as a colocalization signal. Statistical analyses were performed using Prism 6 software (Graphpad Software, La Jolla, CA, USA). Differences between treated and untreated control were estimated using 2-way ANOVA followed by Dunnett's multiple comparisons test. Values were expressed as the mean ±SD and p<0.05 was considered statistically significant.

Statistical analyses were performed using Prism 6 software (Graphpad Software, La Jolla, CA, USA). Differences between treated and untreated control were estimated using 2-way ANOVA followed by Dunnett's multiple comparisons test. Values were expressed as the mean ±SD and p<0.05 was considered statistically significant. Spotted reactions were read in a scintillation counter (Trilux, Perkinelmer).

The polymerase assays were performed as previously described. 51 Briefly, the compounds were added in wells (2 µL, 5% DMSO final concentration), and the enzyme was distributed in wells.

Reactions were started by the addition of the nucleotide mix (100 mM ATP) and were incubated where I is the concentration of inhibitor and 100% of activity is the fluorescence intensity without inhibitor. The MTase activity was determined by filter binding assay as previously described. 50 The Scintillation Counter. DENV3 N7-MTase activity was performed as described above but using of 0.5 μM GpppA2′OMe-RNA74 as substrate. The different protein used for polymerase and MTase assays were produces and purified as preciously describes. 51, 53 Supporting Information. Table S1-S4, 1 H and 13 C NMR spectra can be found in the supporting information.

In a microwave tube 2,6-dichloro-9H-purine 4 (100 mg; 0.53 mmol) and 2-phenoxyethylamine (1.06 mmol) were suspended in n-BuOH (3 mL). NEt3 (258 µL; 1.852 mmol) was added and the tube was heated at 70 °C for 30 min (max µW power input: 100 W; ramp time: 1 min; power max: off; maximum pressure: 260 psi)

General Procedures for the Synthesis of compounds 8a,b: In a microwave tube

TFA (0.259 mmol) was added and the tube was heated under microwave irradiation for two consecutive cycles: 1 st Irradiation cycle: 10 min, 170 °C

°C (max μW power input: 300 W; ramp time: 1 min; power max: off

The combined organic were washed with NH4Cl, brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude material was purified by silica gel flash chromatography using the proper eluent: 8a: CH2Cl2/Formic Acid/MeOH 95:3:2; 8b: CH2Cl2/Formic Acid/MeOH 96.5:3:0.5. N2-(3-fluorophenyl)-N6-(2-phenoxyethyl)-9H-purine-2,6-diamine (8a

-fluorophenyl) hydrazinyl)-N-(2-phenoxyethyl)-9H-purin-2-amine (10a): Yield: 46%. MS (ESI) [M+H] + = 380.29 m/z. 1 H NMR (DMSO-d6

13 C NMR (DMSO-d6

76 (s, 1H), 8.35 (s, 1H), 9.30 (s, 1H), 12.36 (s, 1H). 13 C NMR (CDCl3+CD3OD, 75 MHz): δ 41

-phenoxyethyl)-6-(2-(4-(trifluoromethyl)phenyl) hydrazinyl)-9H-purin-2-amine (10d): Yield: 41%. MS (ESI) [M+H] + = 430.36 m/z. 1 H NMR (DMSO-d6, 300 MHz): δ 3.76 (q, 2H

-phenoxyethyl)-6-(2-(3-(trifluoromethyl)phenyl) hydrazinyl)-9H-purin-2-amine (10e): MS (ESI)

-fluorophenyl)diazenyl)-N-(2-phenoxyethyl)-9H-purin-2-amine (11a): MS (ESI)

+ : 378.28 m/z. 1 H NMR (CDCl3, 400 MHz): δ 4.00 (m, 2H), 4.21 (m, 2H), 6.11 (bs, 1H), 6.94 (m, 3H), 7.27 (m, 3H), 7.50 (q, 1H, J = 8 Hz)

CDCl3 +CD3OD, 100 MHz): δ 41

5-difluorophenyl)diazenyl)-N-(2-phenoxyethyl)-9H-purin-2-amine

12 (s, 1H), 13.65 (s, 1H). 13 C NMR (CDCl3+CD3OD, 100 MHz): δ 41.23, 66.41, 106.91, 107.18, J o u r n a l P r e -p r o o f primer sequences and coordinates, as referred to the H/PF/2013 ZIKV strain (Gen Bank Accession Number KJ776791) and DENV DENV-2 New Guinea C

The sequencing reactions were treated with the X-Terminator®Purification kit (AppliedBiosystems) in a 96-well plate as suggested by the manufacturer, resolved by capillary electrophoresis on the 3130 XL Genetic Analyzer (Applied Biosystems)

Huh-7 cells were seeded 1 × 10 4 cells/well onto 1 cm round glass coverslips, infected with DENV-2 (MOI 0.05), treated with Sofosbuvir (100 µM) or compound 6i (50 µM), and fixed in 4% paraformaldehyde/PBS at different time-points (8-12-16-24 hours)

cells were incubated for 1 hour with AlexaFluor® 488-and 568-labeled secondary antibody diluted in PBS with 0.5% BSA + 0.5% Triton-X 100. Cells were stained with 4',6-diamidino-2-phenylindole (DAPI, 10 min). Coverslips were mounted in Fluoromount Aqueous Mounting Medium and pictures of stained cells were taken through a confocal microscope

Reagents for immunofluorescence (PBS, Triton-X 100, Tween 20, anti-NS3 and anti-NS5 antibodies, and Fluoromount) were the support on the ABTS assay. We also thank Priscila Sutto-Ortiz for excellent technical assistance

BSAA, broad-spectrum antiviral agent

PDD, phenotypic drug discovery; TDD, target-based drug discovery

SYRA, secondary yield reduction assay

DYRA, direct yield reduction assay; PRA, plaque reduction assay

IA, immunodetection assay

RSA, radical scavenging activity; CPE, cytopathic effect

RNA-dependent RNA-polymerase

PR8 H1N1, influenza A Puerto Rico/8/34 H1N1 virus; p2009 H1N1, pandemic A/California/04/09 H1N1 virus

5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay

FLU, influenza; CC50, 50% cytotoxic concentration; IC50, 50% inhibitory concentration

KEYWORDS: Diaminopurine, broad-spectrum antivirals, dengue, zika, west nile virus, influenza

Approved Antiviral Drugs Over the Past 50 Years

Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond

The continued threat of emerging flaviviruses

A Single Mutation in the prM Protein of Zika Virus Contributes to Fetal Microcephaly

Chikungunya and dengue autochthonous cases in Europe

Increased risk for autochthonous vector-borne infections transmitted by Aedes albopictus in continental Europe

The arboviral burden of disease caused by co-circulation and co-infection of dengue, chikungunya and Zika in the Americas

Altered Vector Infectivity, and Antibody-Dependent Enhancement: The Dengue-Zika Interplay

COVID-19 and dengue fever: A dangerous combination for the health system in Brazil

Covid-19 and dengue: Double punches for dengueendemic countries in Asia

Influenza and dengue virus co-infection impairs monocyte recruitment to the lung, increases dengue virus titers, and exacerbates pneumonia

Diagnosing Zika virus infection against a background of other flaviviruses: Studies in high resolution serological analysis

Coronavirus Disease of 2019: a Mimicker of Dengue Infection? SN Comprehensive Clinical Medicine

What Are the Odds of Finding a COVID-19 Drug from a Lab Repurposing Screen?

Designing Multi-Target Drugs

RSC drug discovery series

Rediscovery of Natural Compounds Acting via Multitarget Recognition and Noncanonical Pharmacodynamical Actions

Ribavirin: pharmacology, multiple modes of action and possible future perspectives

Discovery of multi-target antivirals acting on both the dengue virus NS5-NS3 interaction and the host Src/Fyn kinases

Discovery of Multi-Target Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) for

Associated Pulmonary Diseases

Identification of broad-spectrum dengue/Zika virus replication inhibitors by functionalization of quinoline and 2,6-diaminopurine scaffolds

Multi-Target CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach

Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of

Antiviral Compounds Inhibiting Zika and Dengue Virus Replication

Novel Two-Round Phenotypic Assay for Protease Inhibitor Susceptibility Testing of Recombinant and Primary HIV-1 Isolates

Agreement between an In-House Replication Competent and a Reference Replication Defective Recombinant Virus Assay for Measuring Phenotypic Resistance to HIV-1 Protease, Reverse Transcriptase, and Integrase Inhibitors

Redox-Modulating Agents in the Treatment of Viral Infections

Organoselenium compounds from purines: Synthesis of 6-arylselanylpurines with antioxidant and anticholinesterase activities and memory improvement effect

Antioxidant Activity of Synthetic Cytokinin Analogues: 6-Alkynyl-and 6-Alkenylpurines as Novel 15-Lipoxygenase Inhibitors

A Multitarget Approach toward the Development of 8-Substituted

Purines for Photoprotection and Prevention of UV-Related Damage

One-Pot Synthesis of Visible-Light-Responsive 6-Azopurines

Anti-malarial activity of N6-modified purine analogues

Antioxidant Activity Applying an Improved ABTS Radical Cation Decolorization Assay. Free Radic

Identification And Characterization Of Novel Compounds With Broad-Spectrum Antiviral Activity Against Influenza A and B Viruses

Influenza Virus Replication in Lung Epithelial Cells Depends on Redox-sensitive Pathways Activated by NOX4-derived ROS

Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-NCoV) in Vitro

Remdesivir Inhibits SARS-CoV-2 in Human

Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Lack of antiviral activity of darunavir against SARS-CoV-2

Discovery of a β-D-20-Deoxy-2'--fluoro-20-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses

Structure of the Yellow Fever NS5 Protein Reveals Conserved Drug Targets Shared among Flaviviruses

A Structural Overview of RNA-Dependent RNA Polymerases from the Flaviviridae Family

Functional Analysis of Two Cavities in Flavivirus NS5 Polymerase

The Transactions of NS3 and NS5 in Flaviviral RNA Replication

Structure of the Flavivirus Helicase: Implications for Catalytic Activity, Protein Interactions, and Proteolytic Processing

Structure and Flexibility of Non-Structural Proteins 3 and -5 of Dengue-and Zika Viruses in Solution

The C-Terminal 50 Amino Acid Residues of Dengue NS3 Protein Are Important for NS3-NS5 Interaction and Viral Replication

Development of Specific Dengue Virus 2′-O-and N7-Methyltransferase Assays for Antiviral Drug Screening

Novel 2-Phenyl-5-[(E)-2-(Thiophen-2-Yl)Ethenyl]-1,3,4-Oxadiazole and 3-Phenyl-5-[(E)-2-(Thiophen-2-Yl)Ethenyl]-1,2,4-Oxadiazole Derivatives as Dengue Virus Inhibitors Targeting NS5 Polymerase

Biochemical Characterization of the (Nucleoside-2'O)-Methyltransferase Activity of Dengue Virus Protein NS5 Using Purified Capped RNA Oligonucleotides 7MeGpppACn and GpppACn

Zika Virus Methyltransferase: Structure and Functions for Drug Design Perspectives

Serotype-Specific Differences in Dengue Virus Non-Structural Protein 5 Nuclear Localization

Zika Virus NS5 Nuclear Accumulation Is Protective of Protein Degradation and Is Required for Viral RNA Replication

Nucleocytoplasmic Shuttling of the West Nile Virus RNA -dependent RNA Polymerase NS5 Is Critical to Infection

Gutiérrez Castañeda, B. Caveolin-1 in Lipid Rafts Interacts with Dengue Virus NS3 during Polyprotein Processing and Replication in HMEC-1 Cells

Host-Directed Antiviral Therapy

Influenza Virus Infections and Cellular Kinases

Discovery of novel purine derivatives with potent and selective inhibitory activity against c-src tyrosine kinase

Mechanism of Action and Target Identification: A Matter of Timing in Drug Discovery

Opportunities and Challenges in Phenotypic Drug Discovery: An Industry Perspective

Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic

Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro

Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro

The Environmental Pollutant Cadmium Promotes Influenza Virus Replication in MDCK Cells by Altering Their Redox State

Synthesis of Stilbene and Chalcone Inhibitors of Influenza A Virus by SBA -15 Supported Hoveyda-Grubbs Metathesis. Catalysts

Free ADME-Tox Filtering Computations for Chemical Biology and Early Stages Drug Discovery

Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2? ACS Infect

Arbidol as a Broad-Spectrum Antiviral: An Update